Latest / The Science of Skin / Epiduo OTC: Full Clinical Data Deep Dive on Adapalene + Benzoyl Peroxide

Transcript

Epiduo OTC: Full Clinical Data Deep Dive on Adapalene + Benzoyl Peroxide · The Science of Skin

0:00
SPEAKER_00: This episode of the Science of Skin Podcast is sponsored by Galderma.
0:12
SPEAKER_01: Hi, everybody.
0:13
SPEAKER_01: Welcome to the Science of Skin Podcast.
0:15
SPEAKER_01: My name is Dr.
0:15
SPEAKER_01: Ted Lane.
0:16
SPEAKER_01: I am a board-certified dermatologist in Austin, and I'm with my business partner, my co-founder, my co-host, Dr.
0:23
SPEAKER_01: Patty Ferris, who is usually in New Orleans, although now she's in Sag Harbor escaping the heat.
0:30
SPEAKER_01: How are you doing, Patty?
0:31
SPEAKER_02: I'm cool.
0:33
SPEAKER_02: That's all I'm gonna say.
0:34
SPEAKER_01: You are cool.
0:35
SPEAKER_01: You are cool.
0:36
SPEAKER_02: I'm cool in warm ways in warm right now.
0:39
SPEAKER_02: That's for sure.
0:40
SPEAKER_01: Well, I appreciate that.
0:42
SPEAKER_01: So today, Patty, we are talking about the uh OTC conversion of Epiduo.
0:48
SPEAKER_01: So Epiduo, as you know, gosh, it's been a foundational treatment for uh our moderate to severe acne patients uh product in our clinic uh since the mid-2000s.
1:01
SPEAKER_01: Millions of prescriptions have been written for Epiduo.
1:04
SPEAKER_01: I know for me it was kind of, I was just handing it out like candy.
1:08
SPEAKER_01: Uh and now Galderma has done the work and it is available over the counter for our patients.
1:16
SPEAKER_01: And and this episode is sponsored by by Galderma.
1:19
SPEAKER_01: And what I'd like to do, Patty, if you're okay with it, is just talk about the data supporting Epiduo, just to remind everybody how great this product is, which is a fixed combination, Patty, of adaplene.01% and benzoyl peroxide 2.5%.
1:36
SPEAKER_02: Uh I I think we got to give give them a nod for getting this into the OTC market, because as we all know, getting prescriptions for acne is more and more challenging by the minute.
1:49
SPEAKER_02: And uh I can tell you that's one thing that I think most dermatologists are extremely frustrated with is acne's been relegated to a you know cosmetic condition, which is so not correct, but that's the way it's often viewed.
2:05
SPEAKER_02: So for patients to be able to go and pick this up for themselves is really it's that's a total game changer.
2:11
SPEAKER_01: Yeah.
2:11
SPEAKER_01: And I remember when this was when this was um introduced into the market, it was it was such a landmark because benzyl peroxide is just so difficult to formulate.
2:23
SPEAKER_01: Uh it oxidizes everything.
2:25
SPEAKER_01: Remember, benzyl peroxide is antimicrobial, it kills everything, it kind of carpet bombs the microbiome, which is really helpful when you're targeting the the cutie bacterium acnes, uh, but it also doesn't play well with others in the sandbox.
2:39
SPEAKER_01: And so adaplene, which is a synthetic retinoid that was uh developed to be super stable, it is photostable as well, it doesn't break down in the presence of light.
2:51
SPEAKER_01: Uh and so it's it's great because now you can you can have this stable formulation of adaplene and benzoyl peroxide with all these other ingredients included in the formulation to make sure it's all these two ingredients are dispersed properly.
3:06
SPEAKER_01: There's humectants and there's moisturizers and um well tolerated.
3:11
SPEAKER_01: So well tolerated.
3:12
SPEAKER_01: And so actually, that brings up a good point, Patty.
3:15
SPEAKER_01: I uh you can find adaplene plus benzo peroxide from other sources out there, but they aren't the formulation that was tested.
3:25
SPEAKER_01: Um, so and they certainly don't have stability and toxicology testing like we have through Galderma.
3:31
SPEAKER_01: So I don't mess with any other fixed dose combination that's available in the market.
3:36
SPEAKER_01: I only go through the Galderma supported products because I know the testing and the safety behind them.
3:42
SPEAKER_02: Right.
3:42
SPEAKER_02: And and you know how important the formulation is.
3:45
SPEAKER_02: And that that that I think has somehow gotten lost in the world of social media and the promotion of dupes.
3:52
SPEAKER_02: And, you know, just because it has the same things in its formulation doesn't mean it's gonna work the same.
3:59
SPEAKER_01: Exactly.
4:01
SPEAKER_02: Agree 100% on that.
4:03
SPEAKER_01: You know, and Galderma came out with Diffrin, the um the different adapene, the 0.1% adapline that's available for for years now.
4:11
SPEAKER_01: So they brought different over uh to the OTC market, which has really revolutionized the way we treat our mild to moderate acne patients.
4:19
SPEAKER_01: And so it kind of this is the next iteration of going OTC, right?
4:23
SPEAKER_01: Getting uh Epiduo available at a great price point for patients.
4:27
SPEAKER_01: Um you compare that with other Cetophil products to make sure that you've got the CAMP, the cleanse, moisturize, protect uh regimen, which is so important for our acne patients.
4:38
SPEAKER_01: It's all within that kind of Cetophil brand, the the different sub-brand of products uh just makes a ton of sense.
4:46
SPEAKER_01: So uh, Patty, if it's okay, let's just go into kind of the phase three trials.
4:51
SPEAKER_02: Yeah.
4:52
SPEAKER_02: I mean, this this paper was published, the first of them.
4:55
SPEAKER_02: Uh well, they were both published in 2009, but I think we're gonna talk about the one that was the North American study of the combination for the treatment of mild to uh moderate acne.
5:06
SPEAKER_01: Yeah, yeah.
5:07
SPEAKER_01: So this is their their phase three study uh published in QTIS in 2009.
5:12
SPEAKER_01: 60 centers in the US, Puerto Rico, and Canada patients had uh moderate to severe acne, so three or four on the IGA scale.
5:20
SPEAKER_01: They had to have at least 20 inflammatory, 30 non-inflammatory lesions.
5:24
SPEAKER_01: So pretty darn common for the the um type of acne trials that we run.
5:29
SPEAKER_01: Now, because this is a fixed-dose combination patty, we had to show that the combination was better than each of the ingredients alone.
5:36
SPEAKER_02: Individual, but we also should mention the over 1600 patients.
5:40
SPEAKER_02: So this is a huge cohort.
5:41
SPEAKER_01: Yeah, yeah, over 1,600 patients.
5:44
SPEAKER_01: Right.
5:44
SPEAKER_01: So patients are randomized one to one to one to one.
5:47
SPEAKER_01: So one of those ones is placebo, one of those ones is the active, is is the fixed dose combination, and then you've got BPO 2.5% by itself and adapling 0.1% by itself.
5:57
SPEAKER_01: Okay, so those are the four cohorts in this trial.
6:02
SPEAKER_01: And the success rate is just getting to clear or almost clear.
6:06
SPEAKER_01: This was back in the day where IgA success did not mandate a two-grade improvement.
6:11
SPEAKER_01: Okay.
6:12
SPEAKER_01: So all you had to do is get to clear.
6:17
SPEAKER_01: They changed the game after after the study.
6:19
SPEAKER_01: So clear or almost clear, okay.
6:22
SPEAKER_01: And then we looked at other in endpoints as well, percent lesion count reduction uh for inflammatory and non-inflammatory in total.
6:29
SPEAKER_01: And then and then, of course, we have safety.
6:31
SPEAKER_01: Um, when we look at the baseline demographics, the vast these patients in first of all, incredibly consistent throughout the cohorts, which is important to say.
6:40
SPEAKER_01: Uh, almost every cohort had about 50-50 male-female.
6:44
SPEAKER_01: We had every cohort, the average age was about 18.
6:48
SPEAKER_01: Median lesion counts for every cohort were uh in terms of inflammatory, it was about 27.
6:55
SPEAKER_01: For non-inflammatory, 44 to 47.
6:59
SPEAKER_01: It's just incredibly consistent.
7:01
SPEAKER_01: And the total the total number of lesions in every cohort was between 76 to 79.
7:07
SPEAKER_02: So, guys, that's that's crazy, right?
7:10
SPEAKER_01: It's unbelievable.
7:11
SPEAKER_01: So we really had like very similar patients uh in each cohort, so which gives us the idea that we should be able to really assess these the differences between the cohort very nicely.
7:22
SPEAKER_01: When we look at you know, reasons for discontinuation, the subject disposition, um, lack of efficacy is in one to two patients per cohort.
7:31
SPEAKER_01: So incredibly low.
7:33
SPEAKER_01: The reasons for uh in terms of discontinuation due to an AE, 2.7% in the fixed dose combination, one about 1% in the monads by themselves.
7:46
SPEAKER_01: So very low reason for discontinuation as well.
7:50
SPEAKER_01: Let's go into success, okay?
7:52
SPEAKER_01: Because so interesting, Patty.
7:54
SPEAKER_01: Okay.
7:55
SPEAKER_02: Looking at it, it's incredible.
7:56
SPEAKER_01: Incredible, right?
7:57
SPEAKER_01: So again, this is the primary endpoint, which is clear, almost clear on the IGA.
8:03
SPEAKER_01: And what we see is progressive improvement over time.
8:07
SPEAKER_01: Okay, we don't see any kind of plateauing of this graph from week one, two, four, eight, and twelve.
8:13
SPEAKER_01: This is a 12-week study.
8:14
SPEAKER_01: That's another thing to say.
8:15
SPEAKER_01: 12-week studies now, these days, every study is 16 weeks in acne.
8:19
SPEAKER_01: So this is a 12-week study.
8:21
SPEAKER_01: And we saw at week 12 that about 35% of patients achieved clear, almost clear skin on the fixed dose combination, as compared to 22 to 24 percent on the uh for the individual ingredients by themselves.
8:37
SPEAKER_01: And we have statistical significance compared to everything with the fixed dose combinations statistically superior to both a dapplene by itself, benzyl peroxide by itself, and certainly to placebo.
8:48
SPEAKER_02: So you know, the other thing you see, Ted, is a real early uptake with the combination product.
8:54
SPEAKER_02: So that's something you see on the graph right away.
8:56
SPEAKER_02: It takes off much quicker than the individual components.
9:00
SPEAKER_01: Yep.
9:01
SPEAKER_01: So a fast reduction in the IgA.
9:04
SPEAKER_01: And again, about 35% achieving IgA success, which is clear or almost clear at week 12.
9:11
SPEAKER_01: Then when we go into percent change, first of all, in inflammatory lesions, um it this is going to be surprising, I think, Patty, to many people.
9:21
SPEAKER_01: But we see a 67% reduction in the amount of inflammatory lesions and the percentage of inflammatory lesions by week 12.
9:29
SPEAKER_01: Okay.
9:30
SPEAKER_01: And again, there's no plateauing of the slope here.
9:32
SPEAKER_01: It's continuing to decrease.
9:34
SPEAKER_01: And I know from long-term data, Patty, for 12-month data, that we get 70 plus percent reduction in inflammatory lesions.
9:42
SPEAKER_01: So it continues to work well over time.
9:45
SPEAKER_01: So I I think it's important for those who maybe have forgotten this data, or those of you who are new to practice and maybe have never been exposed to the epiduo data, it's yes, it's only 0.1% adaplene, 2.5% benzyl peroxide, but that combination achieved a 67% reduction in inflammatory lesions at week 12.
10:05
SPEAKER_00: Yeah.
10:06
SPEAKER_01: So it's it is a very compelling therapeutic option for our even our moderate to severe patients.
10:13
SPEAKER_01: And this was monotherapy, Patty.
10:15
SPEAKER_01: This, you know, monotherapy, of course, everybody had that cetophyll cleanser and moisturizer.
10:19
SPEAKER_01: Uh, but you know, the placebo group had 37.5.
10:24
SPEAKER_01: And then when we look at adaplene and benzyl peroxide, 52 to 59% total, but 67% total with the with the fixed dose combination, which is statistically superior to everything else.
10:36
SPEAKER_01: Um, so just something to consider in terms of inflammatory lesion count reduction.
10:41
SPEAKER_01: Incredible.
10:42
SPEAKER_01: And then non-inflammatory lesion count, 60% by week 12, and again, superior to everything else.
10:49
SPEAKER_01: So really interesting in terms of IGA success.
10:53
SPEAKER_01: We have statistical superiority at week 12, inflammatory and non-inflammatory statistical superiority.
11:00
SPEAKER_01: And then let's just talk about total lesion counts, which is probably what counts the most.
11:04
SPEAKER_01: 60% in total lesion counts, both the monads, the BPO by itself, the adaplene by itself, only 50% at week 12.
11:12
SPEAKER_01: So what's that, a 20% improvement compared to the monads?
11:15
SPEAKER_01: And then that's incredible.
11:17
SPEAKER_01: Yeah, and again, statistical superiority.
11:20
SPEAKER_01: In turn in terms of total lesion count, we have statistical superiority with a fixed dose combination as early as week four.
11:27
SPEAKER_01: Okay.
11:28
SPEAKER_01: So it it's important to show that there's synergy when you when you have this fixed dose combination in this formulation.
11:36
SPEAKER_01: Okay, again, you can't apply this to any other formulation.
11:39
SPEAKER_01: In this formulation, we have statistical superiority as early as week four.
11:44
SPEAKER_01: Gosh, to have this available over the counter for like 30 bucks, I think, is just I was gonna ask you how much it is, OTC, because I don't know.
11:52
SPEAKER_02: 30?
11:53
SPEAKER_01: Yeah, I think it's literally$30.
11:55
SPEAKER_01: Yeah.
11:55
SPEAKER_01: That's amazing.
11:56
SPEAKER_01: Yeah, it's one one once a day, right?
12:00
SPEAKER_01: And I should say this is all facial acne.
12:02
SPEAKER_01: Okay.
12:03
SPEAKER_01: I I don't have truncal acne data for Epiduo, although I can tell you, you know, just based on my personal use, Epiduo does work nicely on the trunk.
12:12
SPEAKER_01: Um, but it's a it's a thin layer once a day, followed by moisturizer.
12:16
SPEAKER_01: This was applied at night.
12:18
SPEAKER_01: However, we do know that a dappling is photostable, as I mentioned.
12:20
SPEAKER_01: If your patients really want to apply it in the morning, they can do that.
12:23
SPEAKER_02: They certainly can.
12:24
SPEAKER_02: They certainly can.
12:25
SPEAKER_02: And this is also so important in the sort of context of antibiotic resistance.
12:31
SPEAKER_02: You know, I think it would, it, it, it was really such a great option because we were using so many topical antibiotics at that time.
12:40
SPEAKER_01: You're exactly right.
12:42
SPEAKER_01: And, you know, nowadays we s we really think about the full journey of the acne lesion, right?
12:48
SPEAKER_01: Whereas we used to think about scarring and pigmentation as maybe sequelae of acne, we're starting to come around and think of it as actually part of the of the whole life cycle of an acne lesion.
12:59
SPEAKER_01: And we need to address all of that with our therapeutic choices.
13:05
SPEAKER_01: And we certainly do that with Epiduo.
13:08
SPEAKER_01: We know adaplene has an effect on scarring, on atrophic acne scars.
13:12
SPEAKER_01: We also know it has an effect on pigmentation.
13:15
SPEAKER_01: And when you look at some of these before and afters, we're we're looking at kind of the phase three paper where they have before and afters in there.
13:22
SPEAKER_01: You can absolutely see, Patty, right?
13:24
SPEAKER_01: The reduction in PIH, the reduction in atrophic scarring from baseline to week 12.
13:30
SPEAKER_02: Yeah, they're they're impressive before and after pictures.
13:33
SPEAKER_02: It's great.
13:34
SPEAKER_00: This episode of the Science of Skin Podcast is sponsored by Galderma.
13:39
SPEAKER_01: Let's see what else we have.
13:40
SPEAKER_01: And then we're showing, you know, I'm just looking through this paper.
13:42
SPEAKER_01: They have different Fitzpatrick skin types, they have different types of acne.
13:46
SPEAKER_01: So it's just a very compelling alternative.
13:49
SPEAKER_01: And they supported this with a uh a phase 3B paper as well, which was an international, you know, phase 3B is is is meant to support kind of a the registry trials by going to a larger population, maybe a more diverse population.
14:03
SPEAKER_01: And so they they went across the pond and they they did a full international study with their phase 3B, and they showed even in this different patient population, uh varied patient population, almost exactly the same, if not slightly better results in terms of IGA success, in terms of the percent lesion count reduction as well.
14:24
SPEAKER_01: So our gosh, thousands and thousands of patients were included in the phase three and phase three B trials, and we just saw very consistently that we get about 60% of patients, or excuse me, 60% lesion count reduction, and and 30 plus patients, percent of patients achieving that IgA success as well.
14:45
SPEAKER_01: But you don't have to sacrifice tolerability, which is the benefit of the city.
14:49
SPEAKER_02: I was just gonna say it's so nice that especially across Fitzpatrick skin types, you had such good tolerability with this.
14:55
SPEAKER_02: Yeah.
14:56
SPEAKER_02: Because you don't want any retinoids that can cause irritation and exacerbate hyperpigmentation or anything like that.
15:02
SPEAKER_01: Good point.
15:03
SPEAKER_02: This is so well tolerated.
15:05
SPEAKER_01: Yeah.
15:05
SPEAKER_01: And and you know, we we know for some other recent data in regards to sensitive skin that especially for higher Fitzpatrick skin types, they tend to have the most sensitive skin.
15:15
SPEAKER_01: And so the last thing you want is to exacerbate that.
15:18
SPEAKER_01: And and we think about adding a retinoid plus BPO, you think, oh gosh, I'm gonna make I'm gonna light these people up.
15:25
SPEAKER_01: But when we look at the local tolerability data, um, we see, you know, if if one is on the one to one, two, and three, one is mild, two is moderate, three is severe in terms of the rating by the investigator.
15:38
SPEAKER_01: You don't even hit mild in terms of the worst score over the 12 weeks for either erythema, scaling, dryness, or stinging and burning.
15:48
SPEAKER_01: All of them were less than mild.
15:50
SPEAKER_01: And as we would expect with the retinoid patty, we see a little jump early on, week one, two, and then it goes down over time.
15:58
SPEAKER_02: It's kind of efficacy and tolerability.
16:02
SPEAKER_02: Can't ask for anything more with an acne patient, that's for sure.
16:05
SPEAKER_01: Yeah.
16:06
SPEAKER_01: Just looking at this a little bit closer, it looks like the the fixed dose combination maybe is a little bit higher early on in terms of erythema, scaling, dryness, and stinging and burning, but again, much less than mild.
16:16
SPEAKER_01: Yeah.
16:17
SPEAKER_01: And and then it matches the both, uh, in fact, everything.
16:21
SPEAKER_01: It matches placebo or vehicle gel, and then a dappling and BPO after that in terms of all these local skin reactions.
16:27
SPEAKER_01: And then when we when we uh summarize the adverse events, uh let me see here.
16:35
SPEAKER_01: Let me see if there's anything to tell folks here.
16:37
SPEAKER_01: Looks kind of like a nothing burger to me.
16:40
SPEAKER_01: There's um basically 6% of patients in the fixed dose combination had complained of dry skin.
16:47
SPEAKER_01: That's as compared to 4.3 in the adaplene arm and 1.9 in the BPO arm.
16:53
SPEAKER_01: So again, very low.
16:54
SPEAKER_01: Uh kind of expected, honestly.
16:56
SPEAKER_01: Um but you know, overcome you can overcome that with less frequent dosing initially and/or the use of moisturizing.
17:04
SPEAKER_01: So um, gosh, otherwise, guys, everything's incredibly low.
17:09
SPEAKER_01: Beyond that, application site burning, irritation, and itching are all one to two percent with this fixed dose combination.
17:16
SPEAKER_01: So very, very low.
17:17
SPEAKER_01: In terms of AEs leading to discontinuation, less than three percent in the fixed dose combination, so um incredibly low.
17:24
SPEAKER_01: Anything less than five percent to me uh in a phase free trial is is incredible, and and here we have less than three percent.
17:30
SPEAKER_01: So not, you know, in terms of safety, I think we we really show some benefit here with the Epiduo as well.
17:38
SPEAKER_01: And and you know, I don't I don't know.
17:40
SPEAKER_01: In this in this day and age where there's so much hype and hyperbole, it's really nice to go back to these studies that were performed on thousands of patients and just look at the data again and remind everybody that 0.1% adaplene, 2.5% BPO in this in this formulation gives really nice reduction in both IgA as well as total lesion count for our patients as monotherapy.
18:05
SPEAKER_01: We don't have to go crazy and provide people with 17 different products in order to get to um a really nice result.
18:12
SPEAKER_01: Uh and so all this, you know, double cleansing patty and use a tone.
18:18
SPEAKER_02: We tried to debunk that before.
18:22
SPEAKER_02: You're right.
18:22
SPEAKER_02: I mean, it's just it's just gotten beyond.
18:25
SPEAKER_02: Yeah, it's just gotten uh way too complicated.
18:28
SPEAKER_02: But this this is a nice study.
18:30
SPEAKER_02: And to be honest, Ted, I forgot about how good the data was until we reviewed this paper.
18:35
SPEAKER_02: And you did such a great job teasing it out as you always do.
18:40
SPEAKER_02: But I think for everybody out there listening and in practice, this is something that you can tell your patients, you know, this is something they can go and start with.
18:47
SPEAKER_02: I think it's going to give them more benefits, obviously, than just grabbing an adaplene, which is also available OTC and recommended a lot by Durham's.
18:56
SPEAKER_02: But I think this is a better option for all the reasons that you explained.
19:00
SPEAKER_01: Yeah.
19:00
SPEAKER_02: So with that, I guess, you know, maybe we wrap it up just by saying uh thank you for Gal Derma for sponsoring this episode.
19:08
SPEAKER_02: Thank you for bringing forward and paving the way for taking really good acne therapies, putting them over the counter.
19:16
SPEAKER_02: And we're really democratizing, right, Ted, making things that were prescription available to anybody.
19:22
SPEAKER_02: And I also want to emphasize the early results here.
19:25
SPEAKER_02: You know, there's nothing more frustrating than acne for teenagers, especially.
19:29
SPEAKER_02: You know, it's such a stigma.
19:31
SPEAKER_02: And to for them to be able to grab something that within three or four weeks they're going to see a statistically significant result and improvement.
19:39
SPEAKER_02: You know, that's that real that's a life-changing product, in my opinion.
19:44
SPEAKER_01: I love this product for my uh adult female patients as well, where they you know, we're we're trying to get some um skin quality attributes out of anything that we use to enhance the appearance, and we know that adaplene will do that.
19:59
SPEAKER_01: Absolutely.
20:00
SPEAKER_01: You know, early photoaging can be addressed with the adaplene.
20:03
SPEAKER_02: Um I love the patients who come in and say, I need help with pimples and wrinkles.
20:08
SPEAKER_01: Pimples and wrinkles.
20:09
SPEAKER_01: You can hand them this one.
20:10
SPEAKER_01: It's not fair, is it?
20:12
SPEAKER_01: No.
20:13
SPEAKER_01: I do want to spend just a minute talking about you know, compounding this together, these two ingredients together versus the Galdermo formulation.
20:22
SPEAKER_01: And I know I mentioned that early on, but it's something that it bothers me.
20:27
SPEAKER_01: It just bothers me because you got these companies who are spending millions of dollars to formulate these appropriately, to make sure they've got all the right excipients, to ensure they've got the ingredients that will help minimize the local skin reactions.
20:43
SPEAKER_01: And then they spend another trillion dollars going through phase one, two, three.
20:48
SPEAKER_01: And now you got Galderma spending the money to make it OTC, right?
20:52
SPEAKER_01: Which of course is a business decision, but it also so helpful to our acne patients.
20:57
SPEAKER_01: And so if you're a prescriber out there and and and you think compounding is the bee's knees, just uh just think about what you're doing then to innovation in any of the you know disease states that we treat in in dermatology, because uh by taking money away from the pharmaceutical companies, you're taking away the ability to innovate and to support clinical trials.
21:21
SPEAKER_01: And and while you you know you may think you're doing something great for patients, and certainly there are cases where compounding is important and it plays a role, I'm not saying that, but but gosh, there's a reason things are approved by the FDA and cost millions of dollars to to formulate and and get through these trials.
21:39
SPEAKER_01: And and for us to not support them by going back to these, you know, slapdashed formulations thinking they're good for our patients because they may cost less.
21:52
SPEAKER_01: There's a there's a price to pay for that both now and in the future.
21:55
SPEAKER_01: So I I would just urge our colleagues just to to please consider that as As we try and support our pharmacy colleagues and try and get more innovation in our space.
22:05
SPEAKER_01: Trevor Burrus, Jr.
22:06
SPEAKER_02: You know, that's such a great point.
22:07
SPEAKER_02: And as we look at this study where they compared the combination to the individual ingredients, those are the types of studies that compounding pharmacies don't do.
22:19
SPEAKER_02: They throw five things that work for a condition together and say, Here, you can buy this for 30 bucks.
22:26
SPEAKER_02: Well, what is all of that doing?
22:28
SPEAKER_02: Well, you mentioned it doesn't play well with others a lot of times.
22:31
SPEAKER_02: So unless you really understand formulation parameters, what's the pH, what's the proper way to formulate these things, it doesn't necessarily have that same efficacy.
22:41
SPEAKER_02: And this combination was studied in the gold standard of studies, which is comparing it against the individual components.
22:47
SPEAKER_02: So I agree with you 100% on that.
22:50
SPEAKER_02: We learned about that early on with Triluma, you know, that people started knocking off Triluma.
22:55
SPEAKER_02: And this exact protocol type of protocol was done with Triluma.
22:59
SPEAKER_02: I remember that like it was yesterday.
23:02
SPEAKER_02: But, you know, somebody's got to pave the way, and congratulations to companies like Galderma who launched this product and did it in the proper way.
23:11
SPEAKER_01: Yeah.
23:13
SPEAKER_01: All right.
23:13
SPEAKER_01: I'll get off my soapbox.
23:15
SPEAKER_02: Get off the soapbox.
23:16
SPEAKER_02: Let these people go home.
23:19
SPEAKER_01: So listen, everybody, thank you so much uh for joining us for today's episode.
23:23
SPEAKER_01: Again, we covered the data supporting Epiduo, which is now available over the counter at all the common brick and mortars as well as online um distributors for skincare.
23:36
SPEAKER_01: Uh my name is Dr.
23:37
SPEAKER_01: Ted Lane.
23:38
SPEAKER_01: I'm with my my business partner, my co-host, Dr.
23:41
SPEAKER_01: Patty Ferris.
23:41
SPEAKER_01: Thank you so much for listening.
23:43
SPEAKER_01: Uh listen, if you like the episode, give us a five-star rating.
23:45
SPEAKER_01: And we found that the growth of our podcast really occurs through word of mouth.
23:49
SPEAKER_01: So please tell others uh what you learned.
23:51
SPEAKER_01: And if you enjoyed it, we really we would really appreciate that support.
23:54
SPEAKER_01: If you have an idea for future episodes, if you have any questions for us, shoot us a shoot us an email, inquiry at science of skinsummit.com.
24:01
SPEAKER_01: That's inquiry at science of skinsummit.com.
24:05
SPEAKER_01: If you just can't get enough of us, please come to our conferences.
24:08
SPEAKER_01: We've got one uh in our annual Science of Skin Summit occurring September 17th to the 20th in Austin, Texas, at the beautiful Fairmont Hotel.
24:17
SPEAKER_01: Uh, we would love to have you there, whether you're an aesthetician, a PA, an NP, or a dermatologist.
24:23
SPEAKER_01: We're all you're all welcome.
24:25
SPEAKER_01: We're building a learning community for everybody in Austin.
24:29
SPEAKER_01: And um, we've experienced some healthy growth at the conference, and I think you'll you'll get to meet a ton of different exhibitors there, whether they're pharmaceutical companies or skincare companies or companies interested in longevity, including supplements, you'll get it all there.
24:44
SPEAKER_01: Uh, and you'll have a great time because we don't do anything unless we have a good time, right, buddy?
24:48
SPEAKER_02: Absolutely.
24:50
SPEAKER_01: And then we we are crazy enough to start another conference uh in February of 2027 in Scottsdale.
24:56
SPEAKER_02: I'm sure I'm gonna take that we.
24:59
SPEAKER_01: One of us is crazy enough to start the conference in February.
25:03
SPEAKER_01: It's in Scottsdale.
25:04
SPEAKER_01: It's called the Science of Skin Longevity Conference, really focusing on the hottest topic in both dermatology and all of medicine right now.
25:11
SPEAKER_01: But we're focusing on skin longevity with our science of skin longevity.
25:16
SPEAKER_01: And we we're bringing in the world's experts in all facets of longevity medicine.
25:22
SPEAKER_01: Uh, so if you're interested in in coming to that one as well, please just just take a look at our website, science of skinsummit.com.
25:29
SPEAKER_01: Uh, we'd love to have you join us, and thank you so much for listening.
25:41
SPEAKER_00: This episode of the Science of Skin podcast was sponsored by Gal Derma.